Logo 1.png
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
August 29, 2022 08:00 ET | Aeterna Zentaris Inc
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal...
Logo 1.png
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
August 03, 2022 17:30 ET | Aeterna Zentaris Inc
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE...
Logo 1.png
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
May 25, 2022 08:00 ET | Aeterna Zentaris Inc
TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Logo 1.png
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
April 19, 2022 08:05 ET | Aeterna Zentaris Inc
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO,...
Logo 1.png
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
May 17, 2021 08:05 ET | Aeterna Zentaris Inc
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
Logo 1.png
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 22, 2021 16:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
February 16, 2021 22:00 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
February 16, 2021 17:19 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
22157.jpg
Global Biosimilar Growth Hormones Market Report 2020: COVID-19 Impacts, Growth and Changes - Forecast to 2030
February 03, 2021 05:08 ET | Research and Markets
Dublin, Feb. 03, 2021 (GLOBE NEWSWIRE) -- The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Major...
Logo 1.png
Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin
December 07, 2020 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical...